23 Einträge gefunden

1. Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection

   1. Dietz, Julia
   2. Kalinina, Olga V
   3. Vermehren, Johannes
   4. Peiffer, Kai-Henrik
   5. Matschenz, Katrin
   6. Buggisch, Peter
   7. Niederau, Claus

   2020 - Forschungsinformationssystem des UKE
2. Management of hepatic encephalopathy in Germany:a survey among physicians

   1. Labenz, Christian
   2. Adarkwah, Charles C
   3. Wörns, Marcus-Alexander
   4. Miehlke, Stephan
   5. Hofmann, Wolf P
   6. Buggisch, Peter
   7. Galle, Peter R

   2020 - Forschungsinformationssystem des UKE
3. Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions

   1. Dietz, Julia
   2. Vermehren, Johannes
   3. Matschenz, Katrin
   4. Buggisch, Peter
   5. Klinker, Hartwig
   6. Schulze Zur Wiesch, Julian
   7. Hinrichsen, Holger

   2020 - Forschungsinformationssystem des UKE
4. Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R)

   1. Christensen, Stefan
   2. Buggisch, Peter
   3. Mauss, Stefan
   4. Böker, Klaus Hw
   5. Müller, Tobias
   6. Klinker, Hartwig
   7. Zimmermann, Tim

   2019 - Forschungsinformationssystem des UKE
5. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.

   1. Schaefer, Martin
   2. Sarkar, Rahul
   3. Knop, Viola
   4. Effenberger, Susanne
   5. Friebe, Astrid
   6. Heinze, Loni
   7. Spengler, Ulrich

   2012 - Forschungsinformationssystem des UKE
6. The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.

   1. Weich, Viola
   2. Herrmann, Eva
   3. Chung, Tje Lin
   4. Sarrazin, Christoph
   5. Hinrichsen, Holger
   6. Buggisch, Peter
   7. Gerlach, Tilman

   2011 - Forschungsinformationssystem des UKE
7. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.

   1. Sarrazin, Christoph
   2. Schwendy, Susanne
   3. Möller, Bernd
   4. Dikopoulos, Nektarios
   5. Buggisch, Peter
   6. Encke, Jens
   7. Teuber, Gerlinde

   2011 - Forschungsinformationssystem des UKE
8. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).

   1. Benten, Daniel
   2. Schulze Zur Wiesch, Julian
   3. Sydow, Karsten
   4. Koops, Andreas
   5. Buggisch, Peter
   6. Böger, Rainer
   7. Gaydos, Charlotte A

   2011 - Forschungsinformationssystem des UKE - frei zugänglich
9. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.

   1. van Bömmel, Florian
   2. Man, de
   3. Robert, A
   4. Wedemeyer, Heiner
   5. Deterding, Katja
   6. Buggisch, Peter
   7. Buggisch, Peter

   2010 - Forschungsinformationssystem des UKE
10. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.

    1. Berg, Thomas
    2. Weich, Viola
    3. Teuber, Gerlinde
    4. Klinker, Hartwig
    5. Möller, Bernd
    6. Rasenack, Jens
    7. Hinrichsen, Holger

    2009 - Forschungsinformationssystem des UKE
11. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection.

    1. Schulze Zur Wiesch, Julian
    2. Pieper, Dorothea
    3. Stahmer, Ingrid
    4. Eiermann, Thomas
    5. Buggisch, Peter
    6. Lohse, Ansgar W.
    7. Hauber, Joachim

    2009 - Forschungsinformationssystem des UKE
12. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection.

    1. Deterding, K
    2. Wiegand, J
    3. Grüner, N
    4. Hahn, A
    5. Jäckel, E
    6. Jung, M C
    7. Buggisch, Peter

    2009 - Forschungsinformationssystem des UKE
13. Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.

    1. Halangk, Juliane
    2. Sarrazin, Christoph
    3. Neumann, Konrad
    4. Puhl, Gero
    5. Mueller, Tobias
    6. Teuber, Gerlinde
    7. Klinker, Hartwig

    2008 - Forschungsinformationssystem des UKE
14. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.

    1. von Wagner, Michael
    2. Hofmann, Wolf Peter
    3. Teuber, Gerlinde
    4. Berg, Thomas
    5. Goeser, Tobias
    6. Spengler, Ulrich
    7. Hinrichsen, Holger

    2008 - Forschungsinformationssystem des UKE
15. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?

    1. Hennes, Elke
    2. Oo, Ye H
    3. Schramm, Christoph
    4. Denzer, Ulrike W.
    5. Buggisch, Peter
    6. Wiegard, Christiane
    7. Kanzler, Stephan

    2008 - Forschungsinformationssystem des UKE
16. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.

    1. Rodríguez-Torres, Maribel
    2. Govindarajan, Sugantha
    3. Solá, Ricard
    4. Clumeck, Nathan
    5. Lissen, Eduardo
    6. Pessôa, Mário
    7. Buggisch, Peter

    2008 - Forschungsinformationssystem des UKE
17. Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy.

    1. Steffen, M
    2. Cornberg, M
    3. Buggisch, Peter

    2007 - Forschungsinformationssystem des UKE
18. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.

    1. Kronenberger, Bernd
    2. Berg, Thomas
    3. Herrmann, Eva
    4. Hinrichsen, Holger
    5. Gerlach, Tilman
    6. Buggisch, Peter
    7. Spengler, Ulrich

    2007 - Forschungsinformationssystem des UKE
19. Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C.

    1. Wiegand, Johannes
    2. Cornberg, Markus
    3. Aslan, Nuray
    4. Schlaphoff, Verena
    5. Sarrazin, Christoph
    6. Kubitschke, Anne
    7. Buggisch, Peter

    2007 - Forschungsinformationssystem des UKE
20. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.

    1. Wursthorn, Karsten
    2. Lütgehetmann, Marc
    3. Dandri-Petersen, Maura
    4. Volz, Tassilo
    5. Buggisch, Peter
    6. Zollner, Bernhard
    7. Longerich, Thomas

    2006 - Forschungsinformationssystem des UKE